Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares Russell 2000 ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while iShares Russell 2000 ETF trades at $272 (market cap $77.75B). The key difference: iShares Russell 2000 ETF is far larger — about 27.2× Dyne Therapeutics Inc. Common Stock's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares Russell 2000 ETF for 83 Days on average.
| DYN | IWM | |
|---|---|---|
Market Cap | $2.86B | $77.75B |
Volume | 3,341,579 | 27,728,271 |
Sector | Health | — |
52-Week High | $26.78 | $305.06 |
52-Week Low | $14.60 | $229.13 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
IWM trades at $276.71, down 0.42% with bearish technical signals from moving averages. The ETF faces headwinds as small-caps underperform large-caps, with recent Fed rate hikes pressuring the sector. Technical indicators show oversold conditions with RSI at 38.61, while support sits at $276. Recent news highlights IWM's decade-long underperformance versus the S&P 500, raising questions about the small-cap premium.
The outlook remains cautious given macroeconomic pressures and sector rotation away from small-caps. Higher interest rates typically disadvantage small companies with greater borrowing needs, while broader market concentration in tech giants reduces small-cap participation. However, current valuations may offer long-term value if economic conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
